US · guidance
CMS SOM App. C, Tag D5625
§493.1274 Standard: Cytology
(c)(3) For each patient with a current HSIL, adenocarcinoma, or other malignant
neoplasm, laboratory review of all normal or negative gynecologic specimens
received within the previous 5 years, if available in the laboratory (either on-site or
in storage). If significant discrepancies are found that will affect current patient
care, the laboratory must notify the patient’s physician and issue an amended
report.
Probes §493.1274(c)(3)
How does the laboratory track previous cases on an individual patient?
What criteria does the laboratory use to determine discrepancies when reviewing normal
or negative slides from the past five years? How does the laboratory document the
review?
How does the laboratory use the retrospective review to assess the analytic system and
communicate findings to the appropriate staff? Use D5793
History
Rev. 233; Issued: 09-12-25; Effective: 09-12-25; Implementation: 09-12-25
Provenance
- Source
- cms.gov
- Retrieved
- 2026-07-22
- Edition
- som-2026-07-22
- Content hash
95350cee0f43de82af84b509bae000cf4db50121516fb679f5ebb55ad9f5b4e6
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.